Skip to main content
. 2017 Feb 3;8(10):16605–16620. doi: 10.18632/oncotarget.15073

Figure 5. Treatment of GBM cells with anti-GD2-ch14.18/CHO-PLGA-Let-NPs.

Figure 5

± TMZ. Glioblastoma cell lines MZ-304 (A) and RN1 (B) were treated with anti-GD2-ch14.18/CHO-PLGA-Let-NPs or the corresponding control anti-GD2-ch14.18/CHO-PLGA-Veh-NPs with or without temozolomide (150 μM)-supplemented cell media. Treatment of both cell lines with anti-GD2-ch14.18/CHO-PLGA-Let-NPs in combination with TMZ significantly reduced cell numbers when compared to anti-GD2-ch14.18/CHO-PLGA-Veh-NPs+TMZ or anti-GD2-ch14.18/CHO-PLGA-Let-NPs+DMSO treatments alone (n = 3, mean ±SEM, *p < 0.05, **p < 0.01, ***p < 0.001). Notably, for ease of labelling in the above figure anti-GD2-ch14.18/CHO-PLGA-NPs are referred to as anti-GD2-NPs.